Characterization of Oncology Clinical Trials Using Germline Genetic Data

IMPORTANCE: The recent successes of poly-ADP ribose polymerase (PARP) inhibitors and belzutifan support germline genetic data as an exciting, accessible source for biomarkers in cancer treatment. This study hypothesizes, however, that most oncology clinical trials using germline data largely priorit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kammula, Ashwin V., Schäffer, Alejandro A., Rajagopal, Padma Sheila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669814/
https://www.ncbi.nlm.nih.gov/pubmed/36383380
http://dx.doi.org/10.1001/jamanetworkopen.2022.42370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669814/
https://www.ncbi.nlm.nih.gov/pubmed/36383380
http://dx.doi.org/10.1001/jamanetworkopen.2022.42370

Ejemplares similares